BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 26558809)

  • 1. The Incidence of Hypersensitivity Reactions to Pegylated Asparaginase in Children With Acute Lymphoblastic Leukemia: A City-wide Experience.
    Alrazzak M; Beaupin LK; Kinyoun P; Barth M
    J Pediatr Hematol Oncol; 2016 Jan; 38(1):e16-20. PubMed ID: 26558809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of hypersensitivity reactions between intravenous and intramuscular applications of native
    Odaman Al I; Özdemir N; Zengin Ersoy G; Bayram C; Vupa Çilengiroğlu Ö; Arslantaş E; Paslı Uysalol E; Ayçiçek A
    J Oncol Pharm Pract; 2023 Sep; 29(6):1454-1460. PubMed ID: 36942380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of allergic reactions to intravenous and intramuscular pegaspargase in children with acute lymphoblastic leukemia.
    Petersen WC; Clark D; Senn SL; Cash WT; Gillespie SE; McCracken CE; Keller FG; Lew G
    Pediatr Hematol Oncol; 2014 May; 31(4):311-7. PubMed ID: 24498943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.
    Ko RH; Jones TL; Radvinsky D; Robison N; Gaynon PS; Panosyan EH; Avramis IA; Avramis VI; Rubin J; Ettinger LJ; Seibel NL; Dhall G
    Cancer; 2015 Dec; 121(23):4205-11. PubMed ID: 26308766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007.
    Schrey D; Borghorst S; Lanvers-Kaminsky C; Hempel G; Gerss J; Möricke A; Schrappe M; Boos J
    Pediatr Blood Cancer; 2010 Jul; 54(7):952-8. PubMed ID: 20108339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The feasibility of Erwinia asparaginase for pediatric patients who developed an allergic reaction to E.coli asparaginase during treatment of acute lymphoblastic leukemia].
    Takahashi H; Koh K; Kato M; Isobe K; Yasui N; Mori M; Akiyama K; Kikuchi A; Hanada R
    Rinsho Ketsueki; 2013 Apr; 54(4):370-7. PubMed ID: 23666219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
    Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of hypersensitivity reactions to PEG-asparaginase in children after intravenous and intramuscular administration.
    August KJ; Miller WP; Dalton A; Shinnick S
    J Pediatr Hematol Oncol; 2013 Oct; 35(7):e283-6. PubMed ID: 23619117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegaspargase hypersensitivity reactions: intravenous infusion versus intramuscular injection - a review.
    Beaupin LK; Bostrom B; Barth MJ; Franklin I; Jaeger R; Kamath P; Schreiber B; Bleyer A
    Leuk Lymphoma; 2017 Apr; 58(4):766-772. PubMed ID: 27643446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Characteristics of Intravenous PEG-Asparaginase Hypersensitivity Reactions in Patients Undergoing Treatment for Acute Lymphoblastic Leukemia [Formula: see text].
    Browne EK; Moore C; Sykes A; Lu Z; Jeha S; Mandrell BN
    J Pediatr Oncol Nurs; 2018; 35(2):103-109. PubMed ID: 29161979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia.
    Burke MJ; Rheingold SR
    Leuk Lymphoma; 2017 Mar; 58(3):540-551. PubMed ID: 27546298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allergic Reactions Associated with Intravenous Versus Intramuscular Pegaspargase: A Retrospective Chart Review.
    Abbott LS; Zakova M; Shaikh F; Shewaramani N; Punnett A; Dupuis LL
    Paediatr Drugs; 2015 Aug; 17(4):315-21. PubMed ID: 25862348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review.
    Hasan H; Shaikh OM; Rassekh SR; Howard AF; Goddard K
    Pediatr Blood Cancer; 2017 Jan; 64(1):81-88. PubMed ID: 27578304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials.
    Burke MJ; Devidas M; Maloney K; Angiolillo A; Schore R; Dunsmore K; Larsen E; Mattano LA; Salzer W; Winter SS; Carroll W; Winick NJ; Loh ML; Raetz E; Hunger SP; Bleyer A
    Leuk Lymphoma; 2018 Jul; 59(7):1624-1633. PubMed ID: 29115886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
    Plourde PV; Jeha S; Hijiya N; Keller FG; Silverman LB; Rheingold SR; Dreyer ZE; Dahl GV; Mercedes T; Lai C; Corn T
    Pediatr Blood Cancer; 2014 Jul; 61(7):1232-8. PubMed ID: 24436152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
    Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium.
    Mondelaers V; Ferster A; Uyttebroeck A; Brichard B; van der Werff Ten Bosch J; Norga K; Francotte N; Piette C; Vandemeulebroecke K; Verbeke C; Schmidt S; Benoit Y; Lammens T; De Moerloose B
    Br J Haematol; 2020 Jul; 190(1):105-114. PubMed ID: 32057100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia.
    Wenner KA; Vieira Pinheiro JP; Escherich G; Wessalowski R; Jorch N; Wolff J; Stehn M; Kohlschütter A; Boos J; Janka-Schaub GE
    Klin Padiatr; 2005; 217(6):321-6. PubMed ID: 16307417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia.
    Dibenedetto SP; Di Cataldo A; Ragusa R; Meli C; Lo Nigro L
    J Clin Oncol; 1995 Feb; 13(2):339-44. PubMed ID: 7844595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of allergic reactions to pegasparaginase given intravenously versus intramuscularly.
    Pidaparti M; Bostrom B
    Pediatr Blood Cancer; 2012 Sep; 59(3):436-9. PubMed ID: 22021170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.